Blood:转录因子ATF4激活BCL11A转录以沉默胎儿血红蛋白表达

2020-05-01 QQY MedSci原创

HRI激活ATF4,促进BCL11A转录和胎儿血红蛋白沉默。 ATF4以物种选择性方式调控BCL11A。

胎儿血红蛋白再激活仍是治疗镰状细胞病和β-地中海贫血患者的一个至关重要的目标。既往研究人员发现胎儿γ-珠蛋白基因沉默需要红细胞特异性eIF2α激酶HRI的参与,表明HRI可能为提高胎儿血红蛋白水平提供了一个药理靶点。

本研究通过CRISPR-CAS9导向的人红细胞功能丧失性筛查,确定了转录因子ATF4,一个已知的受HRI调节的蛋白,是一种新的γ-珠蛋白调节因子。

ATF4通过与γ-珠蛋白转录抑制因子BCL11A的增强子结合并促进BCL11A的增强子-启动子接触,直接刺激BCL11A的转录。值得注意的是,HRI缺陷小鼠表现出正常的Bcl11a水平,这表明了物种选择性调节,研究人员通过证明小鼠Bcl11a增强子上存在一个在很大程度上都是可有可无的类似的ATF4基序来解释了这一点。

综上所述,本研究揭示了从HRI到ATF4再到BCL11A到γ-珠蛋白的线性信号通路,并阐明了小鼠珠蛋白基因调控模型的潜在局限性。
 
原始出处:
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747390, encodeId=bca31e47390ac, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Oct 22 14:55:58 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716309, encodeId=86871e16309b4, content=<a href='/topic/show?id=85af8363066' target=_blank style='color:#2F92EE;'>#胎儿血红蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83630, encryptionId=85af8363066, topicName=胎儿血红蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7b32200403, createdName=windight, createdTime=Sun Dec 13 09:55:58 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532669, encodeId=2d091532669ba, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537494, encodeId=ab22153e494af, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557958, encodeId=4bdf155e95875, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-10-22 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747390, encodeId=bca31e47390ac, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Oct 22 14:55:58 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716309, encodeId=86871e16309b4, content=<a href='/topic/show?id=85af8363066' target=_blank style='color:#2F92EE;'>#胎儿血红蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83630, encryptionId=85af8363066, topicName=胎儿血红蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7b32200403, createdName=windight, createdTime=Sun Dec 13 09:55:58 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532669, encodeId=2d091532669ba, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537494, encodeId=ab22153e494af, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557958, encodeId=4bdf155e95875, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747390, encodeId=bca31e47390ac, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Oct 22 14:55:58 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716309, encodeId=86871e16309b4, content=<a href='/topic/show?id=85af8363066' target=_blank style='color:#2F92EE;'>#胎儿血红蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83630, encryptionId=85af8363066, topicName=胎儿血红蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7b32200403, createdName=windight, createdTime=Sun Dec 13 09:55:58 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532669, encodeId=2d091532669ba, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537494, encodeId=ab22153e494af, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557958, encodeId=4bdf155e95875, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-05-03 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747390, encodeId=bca31e47390ac, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Oct 22 14:55:58 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716309, encodeId=86871e16309b4, content=<a href='/topic/show?id=85af8363066' target=_blank style='color:#2F92EE;'>#胎儿血红蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83630, encryptionId=85af8363066, topicName=胎儿血红蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7b32200403, createdName=windight, createdTime=Sun Dec 13 09:55:58 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532669, encodeId=2d091532669ba, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537494, encodeId=ab22153e494af, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557958, encodeId=4bdf155e95875, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747390, encodeId=bca31e47390ac, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Oct 22 14:55:58 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716309, encodeId=86871e16309b4, content=<a href='/topic/show?id=85af8363066' target=_blank style='color:#2F92EE;'>#胎儿血红蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83630, encryptionId=85af8363066, topicName=胎儿血红蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b7b32200403, createdName=windight, createdTime=Sun Dec 13 09:55:58 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532669, encodeId=2d091532669ba, content=<a href='/topic/show?id=f33388695c2' target=_blank style='color:#2F92EE;'>#蛋白表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88695, encryptionId=f33388695c2, topicName=蛋白表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79512374813, createdName=xuyu, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537494, encodeId=ab22153e494af, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557958, encodeId=4bdf155e95875, content=<a href='/topic/show?id=6dcc2935bd' target=_blank style='color:#2F92EE;'>#ATF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2935, encryptionId=6dcc2935bd, topicName=ATF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7df414933799, createdName=appleandpeer, createdTime=Sun May 03 00:55:58 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-05-03 appleandpeer

相关资讯

Brit J Heamatol:同型半胱氨酸与镰状细胞病患者微血管病变的严重程度有关

年龄和同型半胱氨酸浓度是SCD患者微血管病变的独立预测因子。

FDA授予FT-4202治疗镰状细胞病的孤儿药称号

专注于罕见血液学疾病和癌症的临床阶段生物制药公司FORMA近日宣布,美国FDA已授予其FT-4202孤儿药称号,FT-4202目前正处于临床开发中,可作为镰状细胞病(SCD)的潜在疗法。

Blood:镰状细胞病和β-地中海贫血胎儿血红蛋白诱导表达的异质性机制

在全基因转录组、蛋白质组和已知HbF调节因子的表达中,F-红细胞与非HbF表达细胞高度相似。

Blood:预防性抗凝或可降低镰状细胞病血管阻塞性危象的发病率

血管阻塞性危象(VOC)是镰状细胞病(SCD)发病和住院的主要原因。但目前只有三种治疗方法(羟基脲、l-谷氨酰胺和crizanlizumab)被批准用于治疗SCD。这些药物限制了血管阻塞性危象的持续时间、严重程度和发生频率。凝血激活是SCD的一个标志。对SCD动物模型的研究表明,凝血可导致慢性炎症和与SCD相关的终末器官损伤。但凝血是否直接导致引发VOC的微血管停滞仍是不明确。在本研究中,研究人员

Blood:镰状细胞病患者不同状态时的血浆微粒对内皮细胞的影响不同

SS患者危重时释放的血浆微粒可增加内皮细胞ICAM-1水平和中性粒细胞黏附。 羟基脲治疗降低了微粒上暴露的磷脂酰丝氨酸,从而破坏了其促炎特性。

Blood:输血可逆转镰状细胞病的异常血管生成

中心点:缓慢的RBC流动和血管堵塞触发了HIF-1α诱导的异常血管生长的促血管生成环境。在SCD小鼠中,输血可逆转新血管的生成,突出了BM血管系统的可塑性。摘要:镰状细胞病(SCD)是一种高发病率、高死亡率的单基因红细胞病。本文首次报道了SCD对骨髓(BM)血管生态位(对造血至关重要)的影响。研究人员在SCD小鼠中发现了一个无组织的、结构异常的BM血管网络,该BM腔的大部分都是高度弯曲的小动脉,以